Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The protections extend through at least 2035, with the potential for further extensions
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
The approval comes after a systematic review of published literature
Subscribe To Our Newsletter & Stay Updated
